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ANDREW CORWIN, AND J. KEVIN BAIRD
U.S. Naval Medical Research Unit 2, Jakarta, Indonesia; Center for Tropical Diseases, Ho Chi Minh City, Vietnam;
Rollins School of Public Health, Emory University, Atlanta, Georgia
Abstract. We investigated the prevalence of infection with hepatitis B virus among adult Vietnamese patients
hospitalized for severe Plasmodium falciparum malaria. Sera from patients admitted with severe malaria in Ho Chi
Minh City, Vietnam, between May 1991 and January 1996 were assayed for hepatitis B surface antigen (HBsAg) by
a commercial enzyme-linked immunosorbent assay kit. The overall prevalence of HBsAg was 23.77% (77 of 324).
This was higher than reported estimates of prevalence in the general catchment population for the study hospital
(mean, 9.8%; range, 9–16%). No association was found between risk of death caused by severe malaria and HBsAg.
Patients admitted with cerebral malaria had a slightly greater risk of registering positive for HBsAg (relative risk,
1.28; 95% confidence interval, 1.04–1.58) relative to other manifestations of severe malaria. Chronic infection with
hepatitis B virus may be a risk factor for severe malaria.
Despite remarkable achievements in reducing malaria mor-
tality, malaria remains the most common cause of morbidity
and mortality in Vietnam. Of the 71.6 million population, 41.9
million are at risk for malaria; 15 million live in malaria-
endemic areas.1 The majority of people with malaria are not
admitted to the hospital. Instead, they receive oral therapy on
an outpatient basis. People who develop severe malaria and
enter the hospital represent a minority of patients.
This report examines the association of infection with
hepatitis B and severe malaria and the impact of that factor
on survival. Hepatitis B, a double-stranded DNA virus of
the hepadnoviridae family, infects 15% of people in South-
east Asia.2 Globally,  2 billion people are infected; 350
million of which are asymptomatic carriers of the virus.3 The
infection kills  1 million carriers annually, with mortality
generally associated with complications of cirrhosis, hepa-
tocellular carcinoma, and, rarely, fulminant liver failure dur-
ing acute infection.4,5
Coendemic falciparum malaria and acute hepatitis B occur
through much of Southeast Asia, Africa, and the tropical
Americas. Both diseases represent key threats to public
health. To our knowledge, large studies evaluating the effect
of acute hepatitis B infection on risk of severe disease and
death caused by falciparum malaria have not been reported.
We hypothesized that acute hepatitis B may exacerbate the
risk of sequelae with infection by Plasmodium falciparum.
By assaying for hepatitis B surface antigen, a marker for
active infection, among patients admitted to hospital in Vi-
etnam and enrolled into a treatment trial for severe malaria,
we were able to test this hypothesis.6
Between May 1991 and January 1996, a randomized, dou-
ble-blind controlled trial was conducted by Hien and others6
to compare artemether to quinine for the treatment of severe
malaria in Vietnamese adults. The study took place in a re-
search ward at the Center for Tropical Diseases in Ho Chi
Minh City, Vietnam. Severe malaria was defined as having
one or more of the following: cerebral malaria (Glasgow
Coma Scale  11), anemia (hematocrit  20%) with a par-
asite count  100,000/L, jaundice (serum bilirubin  2.5
mg/dL) with a parasite count  100,000/L, renal impair-
ment (urine output  400 mL/24 hr and serum creatinine 
3 mg/dL), hypoglycemia (blood glucose  40 mg/dL), hy-
perparasitemia ( 10%), or shock (systolic blood pressure
 80 mm Hg with cool extremities). This definition of se-
vere malaria includes 2 criteria considered supporting by the
World Health Organization (WHO), hyperparasitemia and
jaundice, and does not include 5 criteria included by WHO:
respiratory distress, repeated convulsions, spontaneous
bleeding, acidosis, and hemoglobinuria.
Inclusion criteria included the following: age  14 years,
not in the first trimester of pregnancy, no intravenous drug
abuse, and receipt of  3 g quinine or 2 doses of any artem-
isinin derivatives in the previous 48 hr. Eligible subjects
were enrolled after informed consent was obtained from the
patients or their guardians.6 A total of 560 patients were
enrolled and randomly assigned to receive either artemether
or quinine dihydrochloride intramuscularly, according to the
regimens described by Hien and others.6 Artemether proved
as safe and effective as quinine.
Assessable sera samples were obtained from 326 of these
subjects. Samples from the remaining subjects were exhaust-
ed in a battery of other tests. Samples were collected by
disposable syringe, centrifuged, serum aspirated, and main-
tained for the first 3 months at 20C. Samples were then
transferred to a 70C freezer and stored at the Institute for
Clinical Research in Tropical Medicine, Hanoi, Vietnam.
The U.S. Naval Medical Research Unit 2 in Jakarta, Indo-
nesia, analyzed the samples with the commercially available
Auszyme monoclonal diagnostic kit for the detection of hep-
atitis B surface antigen in serum or plasma (Abbott Labo-
ratories, Singapore) according to the manufacturer’s instruc-
tions.
Results were expressed as means or frequencies of posi-
tive and negative results and were analyzed by the unpaired
Student’s t-test or by the Mantel-Haenszel test. The chi-
square test was used to assess differences in proportions. P
 0.05 was considered statistically significant. Logistic re-
gression was used to evaluate the relationship between sev-
eral potential confounders and death from severe malaria.
Analysis was carried out by SPSS version 8.0 (SPSS, Chi-
cago, IL) and Epi Info version 6 (Centers for Disease Con-
trol and Prevention, Atlanta, GA).
The mean age of severe malaria subjects was 33 years
(standard deviation, 13), with a range of 15–78 years. Se-
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TABLE 1
Characteristics of patients of admission according to hepatitis B status
Characteristic HBsAg positive HBsAg negative P value
Age (years)
Median
Range
Sex (% male)
Pregnant (%)
29
15–71
57/77 (74.0)
3/77 (3.9)
30
15–78
182/247 (73.7)
11/247 (4.6)
0.55
0.95
0.83
Intravenous drug use (%)
Treatment regimen (% receiving quinine)
Cerebral malaria* (%)
Shock† (%)
Jaundice‡ (%)
0/76 (0.0)
45/77 (58.4)
49/77 (63.6)
12/77 (15.6)
31/73 (42.5)
2/236 (0.8)
121/247 (49.0)
122/246 (49.6)
28/247 (11.3)
126/240 (52.5)
0.42
0.15
0.03
0.32
0.13
Renal failure§ (%)
Severe anemia¶ (%)
Fever# (%)
Transfusion (%)
Pulmonary syndrome** (%)
Convulsions
17/77 (22.1)
2/77 (2.6)
67/77 (87.0)
13/77 (16.9)
26/77 (33.8)
8/77 (10.4)
76/243 (31.3)
18/245 (7.3)
194/247 (78.5)
63/246 (25.6)
96/247 (33.1)
23/247 (9.3)
0.12
0.13
0.10
0.12
0.42
0.78
* Glasgow Coma Scale 11.
† Systolic blood pressure 80 mm Hg with cool extremities.
‡ Serum bilirubin 3.0 mg/dL.
§ Serum creatinine 3.0 mg/dL.
¶ Hematocrit 15%.
# Temperature 37.5C.
** Any one of the following: acute respiratory failure, pulmonary distress, or pulmonary edema.
HBsAg  hepatitis B surface antigen.
TABLE 2
Assessment of outcome
Variable
HBsAg positive(%)
HBsAg negative(%)
Relative risk
(95% confidence interval) P value
Prevalence of death 11/76 (14.5) 36/247 (14.6) 0.99 (0.53–1.85) 0.98
Relative risk is for the HBsAg-positive group. Groups were compared via the Mantel-Haenszel test. HBsAg  hepatitis B surface antigen.
roprevalence of hepatitis B surface antigen (HBsAg) was 77/
324 (23.8%). The death rate among patients with severe ma-
laria was 47/323 (14.6%). Table 1 lists the demographic and
clinical characteristics of subjects, comparing these between
those positive and negative for HBsAg. The only statistically
significant difference between HBsAg-positive and -negative
subjects was in frequency of cerebral malaria: 64 versus 50%
(P  0.03). The relative risk of cerebral malaria with HBsAg
was 1.28 (95% confidence interval [CI], 1.04–1.58, P 
0.03). The frequency of jaundice, renal failure, severe ane-
mia, and the necessity of transfusion were all lower among
HBsAg-positive subjects, but these differences were not sta-
tistically significant.
Table 2 lists the death rate stratified by HBsAg status.
HBsAg positivity carried no elevated risk of death compared
with patients without evidence of hepatitis B infection. Mul-
tivariate logistic regression analysis controlling for age, sex,
pregnancy, and treatment regimen revealed no association be-
tween a higher risk of death and HBsAg positivity. Age was
modeled as a categorical variable with the following groups:
 25 years, 26–35 years, 36–50 years, and  50 years. The
adjusted odds ratio (95% CI) was 0.95 (0.44–2.00), similar to
the crude odds ratio of 0.99 (0.45–2.16). The sample of an-
alyzable sera in this study would have detected a  13%
difference in incidence of death with 80% power. The analysis
thus reveals that HBsAg in serum at the time of admission for
severe malaria was not a significant risk factor for death as
an outcome for the treatment regimens applied.
HBsAg, the outer coat protein of the virus, is a marker for
acute infection or a chronic carrier state. HBsAg is detectable
for 2–15 weeks after exposure and then disappears in 90%
of people infected during convalescence. In the remaining
10%, HBsAg does not clear. These people become chronic
carriers. The patients positive for HBsAg in this study were
not suffering acute hepatitis, but were presumably nearly all
chronic carriers, although we cannot exclude with certainty
that some patients may have had a resolving acute infection.
The cross-sectional prevalence of HBsAg (e.g., at admission
to hospital with severe malaria) includes those recovering
from acute infection and the cumulative proportion of chron-
ic carriers in the population.
The prevalence of HBsAg in subjects with severe malaria
was 23.77% (77/324), higher than in cross-sectional esti-
mates from the general adult population of the region. The
study by Kakumu and others represents an exception to this
as the population surveyed included children (mean age, 28
years; range, 2–81 years).2 Table 3 summarizes measure-
ments of the prevalence of HBsAg in populations from which
the severe malaria patients were drawn and compares these
to HBsAg prevalence in those patients. In all instances, the
prevalence among subjects with severe malaria was signifi-
cantly higher (P  0.001). Measurements of the prevalence
of HBsAg in the general population ranged 9–16%.7,8 The
lower range, 3.1–5.7%, occurred among residents of rural
areas of Ho Chi Minh City. We considered 9.8% HBsAg
positivity reported from the large study of Tran and others8
a surrogate control for the severe malaria cases we evalu-
ated.
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TABLE 3
History of HBsAg prevalence studies in Ho Chi Minh City, Vietnam
Date of study
Population of
Ho Chi Minh City
Prevalence of HBsAg(%)
Chi-Square test statistic*
(P value)
1996
1993
1992
Rural area2
Subpopulations7
Overall
Range
Blood donors9
5.7 (51/890)
10.5 (64/610)
8–14%
3.1 (15/491)
81.91 (0.001)
29.09 (0.001)
83.61 (0.001)
1989–1991 Subpopulations8
Overall in normal population†
Range in normal population†
9.8 (3,837/39,080)
9–16%
69.87 (0.001)
* Comparing the prevalence in patients with severe malaria with each population. HBsAg  hepatitis B surface antigen.
† Excluding intravenous drug abusers, patients with hepatitis, and patients with liver cancer.
Excluding intravenous drug abusers, hepatitis patients,
and liver cancer patients yielded a population of 39,080 sub-
jects, closely approximating the population from which our
sample was drawn. Using that estimate of normal risk of
HBsAg positivity, the odds ratio for the likelihood of HBsAg
positivity in patients with severe malaria versus the normal
population was 2.9 (95% CI, 2.19–3.73, P  0.0001). Ob-
viously, a prospective case control study would have pro-
vided a more accurate estimate of this ratio. Finally, malaria
tends to be a rural disease in Vietnam, where prevalence of
hepatitis B is relatively low. If the severe malaria patients at
Ho Chi Minh Hospital came predominately from rural areas
with relatively low rates of hepatitis B, the relative risk of
concurrent events would be considerably higher. Therefore,
we considered the 2.9 odds ratio of HBsAg in severe malaria
patients versus the normal population to be a conservative
indirect estimate of elevated risk of severe malaria with hep-
atitis B infection. This finding warrants studies that directly
measure the risk of severe malaria with hepatitis B disease.
Our analysis, which was based on samples collected in
the setting of a therapeutic trial, suggests that acute hepatitis
B infection may exacerbate falciparum malaria, causing an
elevated risk of admission to the hospital for severe malaria.
The analysis lacked carefully selected controls for the severe
malaria cases and applied a relatively crude classification of
hepatitis B disease. In addition, it is possible that some sam-
pling bias existed because sera samples were not available
from all patients. Last, because this study included only adult
subjects, the conclusions cannot be automatically extrapo-
lated to children. The findings nonetheless point to the pos-
sibility of an interaction between these diseases that may
increase the risk of morbidity and mortality for the many
millions of people exposed to endemic risk of both infec-
tions. The mechanism of this apparent increase in suscepti-
bility is not known. Perhaps chronic hepatitis B carriers are
less efficient at limiting parasite multiplication. There was
no suggestion that hepatitis B carriers were older or more
likely to come from malaria endemic areas, which might
imply a failure to develop specific protective immunity. Un-
derstanding this relationship may help refine strategies in-
tended to diminish disease and death caused by malaria.
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